EXHIBIT C

MARK-UP VERSION OF AMENDED CLAIMS

IN U.S. APPLICATION SERIAL NO. 09/724,396
ATTORNEY DOCKET NO. 10271-007

73. A sustained release formulation comprising [one or more antibodies or] palivizumab or one or more fragments thereof that immunospecifically bind to one or more RSV antigens.

74. A pharmaceutical composition adapted for pulmonary delivery comprising [one or more antibodies or] palivizumab or one or more fragments thereof that immunospecifically bind to one or more RSV antigens [for pulmonary delivery] and a pharmaceutically suitable carrier.

85. A method of preventing a RSV infection in a mammal, said method comprising administering to said mammal a prophylactically effective amount of the sustained release formulation of claim 73[, 75, 77, 79, 81, or 83].

86. A method of treating or ameliorating one or more symptoms associated with a RSV infection in a mammal with a RSV infection, said method comprising administering to said mammal a therapeutically effective amount of the sustained release formulation of claim 73[, 75, 77, 79, 81, or 83].

87. A method of preventing a RSV infection in a mammal, said method comprising administering to the lungs of said mammal a prophylactically effective amount of the pharmaceutical composition of claim 74[, 76, 78, 80, 82, or 84].

88. A method of treating or ameliorating one or more symptoms associated with a RSV infection in a mammal with a RSV infection, said method comprising administering to the lungs of said mammal a therapeutically effective amount of the pharmaceutical composition of claim 74[, 76, 78, 80, 82, or 84].

180. A method of preventing a RSV infection in a mammal, said method comprising administering to the lungs of said mammal a first dose of a prophylactically effective amount of a composition comprising [one or more antibodies or] palivizumab or one or more fragments thereof that immunospecifically bind to one or more RSV antigens, wherein said prophylactically effective amount results in a prophylactically effective concentration of at least 20 ng per mg of lung protein at least 20 days after the administration of said first dose and prior to the administration of a subsequent dose.

181. A method of treating or ameliorating one or more symptoms associated with a RSV infection in a mammal infected with RSV, said method comprising administering to the lungs of said mammal a first dose of a therapeutically effective amount of a composition comprising [one or more antibodies or] palivizumab or one or more fragments thereof that immunospecifically bind to one or more RSV antigens, wherein said therapeutically effective amount results in a therapeutically effective concentration of at least 20 ng per mg of lung protein at least 20 days after the administration of said first dose and prior to the administration of a subsequent dose.

186. The method of claim 180 or 181, wherein said [antibodies or antibody] palivizumab or fragments thereof are administered by a nebulizer or inhaler.

187. The method of claim 180 or 181, wherein said [antibodies or antibody] palivizumab or fragments thereof are administered intramuscularly, intravaneously or subcutaneously.

189. The method of claim 180 or 181, wherein the mammal is a human subject, a human subject which has had a bone marrow transplant, an elderly human subject, or a human subject which has cystic fibrosis, bronchopulmonary dysplasia, congenital heart disease, congenital immunodeficiency or acquired immunodeficiency.

190. The method of claim 180 or 181, wherein the mammal is a human infant.

191. The method of claim 180 or 181, wherein the mammal is a human infant born prematurely or is at risk of hospitalization for a RSV infection.